Explore the options in current treatment of chronic lymphocytic leukemia (CLL). Experts highlight recent data and discuss the potential impact to your clinical practice. Don’t miss out!
0.75 AMA PRA Category 1 Credit™
Mar 15, 2019
Mar 15, 2020
John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
London, United Kingdom
Arnon P. Kater, MD, PhDAcademic Medical Center
Amsterdam, The Netherlands
- Front-line treatment of CLL
- CLL treatment second line and beyond
This educational activity is intended for hematologists, oncologists, and other healthcare professionals (all practicing outside of the United States) involved in the management of CLL.
After successful completion of this educational activity, participants should be able to:
- Discuss patient, treatment, and disease-related factors that influence treatment selection
- Discuss key efficacy and safety clinical trial data on novel agents and combination therapies in CLL and their potential for incorporation into clinical practice
- Utilize strategies for the identification of treatment-related adverse events
This educational activity is supported by a grant from AbbVie.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 45 minutes
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high- quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Gribben has disclosed that he has received consulting fees from AbbVie, Celgene Corporation, Gilead, Janssen, Pharmacyclics, and Roche. He has performed contracted research for Acerta, Celgene Corporation, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kater has disclosed that he has received consulting fees from AbbVie, Genentech, Janssen, Roche, and Sunesis Pharma. He has received research funding from AbbVie, Celgene Corporation, Janssen, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
Briana Betz, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
Susan McKinney (editorial content reviewer) – no financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.